A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma.

Trial Profile

A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2012

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2009 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Actual patient number (47) added as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top